
    
      The purpose of this study is to evaluate the safety and tolerability of QR-110 administered
      via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
      Subjects will receive QR-110 in one eye every 3 months, for a maximum of 4 doses. Up to 3
      dose levels of QR-110 will be evaluated.
    
  